碳酸镧治疗维持性血液透析疗效及对患者冠状动脉钙化的影响

doi:10.3969/j.issn.1006-6233.2020.08.032

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1197 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effects of lanthanum carbonate (LC) in maintenance hemodialysis (MHD) and the influence on coronary artery calcification (CAC). Methods: A total of 105 hyperphosphatemia patients who underwent MHD and were admitted to the hospital from August 2018 to July 2019 were enrolled as study objects. They were divided into control group (n=52) and observation group ( n=53) by simple random grouping method. The former was treated with calcium carbonate, while the latter was treated with LC. The levels of serum calcium (Ca), serum phosphorus (P), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP) and fibroblast growth factor (FGF-23), left ventricular mass index (LVMI), coronary artery calcification scores (CACS) before and after treatment and adverse reactions were compared between the two groups. Results: The effective rate of treatment in observation group was better than that in control group (P<0.05). Differences of serum Ca, P, iPTH, FGF-23 and ALP levels in observation group before and after treatment were larger than those in control group (P<0.05), while the differences of LVMI and CACS were smaller than those in control group (P<0.05). There was no significant difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion: The curative effect of LC is good on MHD combined with hyperphosphatemia, which can improve CAC in patients.

Key words： Lanthanum carbonate Maintenance hemodialysis Coronary artery Calcification

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.032 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1371

[1] Dhakshinamoorthy J , Elumalai R P , Dev B , et al. Assessment of abdominal aortic calcification in predialysis chronic kidney disease and maintenance hemodialysis patients[J]. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28(6):1338~1348.
[2] Shin D H , Lee Y K , Oh J , et al. Vascular calcification and cardiac function according to residual renal function in patients on hemodialysis with urination[J]. PLoS ONE, 2017, 12(9):e0185296.
[3] 余梦迪, 欧阳沙西, 罗莉, 等.碳酸镧与碳酸钙对血液透析患者冠状动脉钙化进展影响的比较[J].中国现代医学杂志, 2015, 25(30):81~85.
[4] 彭菲, 刘鹏, 施文剑, 等.碳酸镧应用于高磷血症维持性血液透析患者的长期临床疗效和安全性[J].中国新药与临床杂志, 2016, 35(10):724~729.
[5] Chang Y M , Tsai S C , Shiao C C , et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients[J]. Clinical & Experimental Nephrology, 2017, 21(5):917~918.
[6] 江艳, 黄珍伦, 聂凌.碳酸镧治疗尿毒症维持性血液透析患者高磷血症的临床观察[J].中国药房, 2017, 28(20):2787~2789.
[7] 付洁琼, 李英.慢性肾脏病-矿物质与骨异常相关新型生物标志物的研究进展[J].中国中西医结合肾病杂志, 2018, 19(5):463~465.
[8] Moldovan D , Rusu C , Kacso I M , et al. Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis[J]. Clujul Medical, 2015, 89(1):94~103.
[9] Momoyo O , Masafumi F , Takatoshi K . Vascular calcification - pathological mechanism and clinical application. vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Clinical Calcium, 2015, 25(5):645~653.
[10] Shang D , Xie Q , Ge X , et al. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients[J]. BMC Nephrology, 2015, 16(1):107.
[11] 赵文静, 褚以德, 王宁宁, 等.血清成纤维细胞生长因子23在维持性血液透析患者血管钙化中作用的研究进展[J].山东医药, 2016, 56(37):104~106.